Stifel analyst Rick Wise maintains $Abbott Laboratories (ABT.US)$ with a buy rating, and adjusts the target price from $115 to $130.
According to TipRanks data, the analyst has a success rate of 57.8% and a total average return of 3.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
Following Q3 results, modest adjustments have been made to the forecasting model, indicating that Abbott is well-positioned to handle any competitive pressures from pulsed field ablation. Additionally, the prospects of leadless pacing may contribute to an acceleration of cardiac rhythm management growth to exceed 3%. Despite an excellent setup and strong operational execution, it is suggested that Street expectations are currently reflected in the valuation, which appears fair when compared with industry peers.
Abbott's Q3 sales exceeded expectations, bolstered by the strong performance of MedTech and the demand for COVID tests. The company also reaffirmed its organic growth guidance for FY24 and slightly raised the midpoint of its EPS forecast. Despite the positive results, the valuation and ongoing litigation present concerns, though the company's performance provides a positive outlook.
Abbott's management has indicated optimism about the company's capability to maintain high-single-digit revenue growth and double-digit earnings growth moving forward. The CEO's assertion that high-single digit revenue growth and 10% earnings per share growth is a realistic baseline reflects confidence in the company's trajectory. Abbott appears to be favorably positioned with several new offerings in the rapidly expanding Diabetes Care and Structural Heart sectors, suggesting the company's medical device portfolio is primed for robust growth in the MedTech industry.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Rick Wise維持$雅培 (ABT.US)$買入評級，並將目標價從115美元上調至130美元。
根據TipRanks數據顯示，該分析師近一年總勝率為57.8%，總平均回報率為3.9%。
此外，綜合報道，$雅培 (ABT.US)$近期主要分析師觀點如下：
在Q3的業績結果後，對預測模型進行了適度調整，表明雅培公司有能力處理來自脈衝場消融的任何競爭壓力。此外，無導聯起搏的前景可能有助於加速心臟節律管理增長超過3%。儘管佈局優良，運營執行強勁，但街頭預期目前已反映在估值中，與行業同行相比，估值看起來是公平的。
雅培公司的Q3銷售超出預期，得益於醫療技術表現強勁和COVID檢測需求的增加。該公司還重申了FY24的有機增長指引，並略微提高了EPS預測的中間點。儘管結果積極，但估值和持續性訴訟仍存在擔憂，儘管公司的表現提供了積極的展望。
雅培公司管理層表示樂觀，認爲公司有能力保持高個位數的營業收入增長和兩位數的收益增長。首席執行官斷言，高個位數的營收增長和10%的每股收益增長是一個現實的基準，反映了對公司發展路徑的信懇智能。雅培公司似乎佔據有利地位，其在迅速擴展的糖尿病護理和結構心臟領域推出了幾款新產品，這表明公司的醫療器械組合已經做好準備在醫療技術行業蓬勃增長。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
